PFE Form 4: Taraporevala Adds 1,471.743 Deferred Phantom Units

Rhea-AI Filing Summary

Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), reported the acquisition of 1,471.743 phantom stock units on 09/30/2025. The filing shows these units represent deferred director compensation that may be settled in cash or common stock at the director's election following retirement. The units correspond to 1,471.743 underlying shares with an indicated per-share price of $25.48, and the report lists 23,444.776 shares beneficially owned by the reporting person after the transaction. The Form 4 was signed on 10/02/2025 by an attorney-in-fact, Shanice A. Reid.

Positive

• 1,471.743 phantom stock units were acquired and reported on 09/30/2025
• The units are explicitly disclosed as deferred director compensation settled in cash or common stock

Negative

• None.

Insights

Corporate Governance Expert

Director reported deferred-compensation units equal to 1,471.743 shares on 09/30/2025.

The form documents a grant/acquisition of 1,471.743 phantom stock units that are part of deferred director compensation and will be settled in cash or common stock at the director's election following retirement. This is an administrative disclosure required under Section 16 and signals routine director compensation activity rather than a market trade.

The filing also shows the reporting person holds 23,444.776 shares after the transaction; this figure is the post-transaction beneficial ownership disclosed on the Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Taraporevala Cyrus

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Units	(1)	09/30/2025		A		1,471.743		(2)	(2)	Common Stock	1,471.743	$25.48	23,444.776	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

	/s/ Shanice A. Reid, by power of atty., for Cyrus Taraporevala	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pfizer director Cyrus Taraporevala report on Form 4 (PFE)?

The Form 4 reports acquisition of 1,471.743 phantom stock units on 09/30/2025, part of deferred director compensation.

How will the phantom stock units reported by Cyrus Taraporevala be settled?

The filing states the units are settled in cash or common stock at the director's election following retirement.

How many Pfizer shares does the reporting person beneficially own after the transaction?

The Form 4 shows 23,444.776 shares beneficially owned following the reported transaction.

What price is shown for the underlying shares in the Form 4?

The disclosure lists an indicated per-share price of $25.48 for the underlying common stock.

When was the Form 4 signed and filed?

The signature block shows the form was signed by proxy on 10/02/2025.